anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
At the time of hospital discharge, the control group will be discharged without receipt of home monitoring, and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure) and SPO2 (pulse oximetry) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for four weeks and have their NIBP, HR (heart rate), SPO2 and pain scores evaluated twice a day for two weeks.
The invention provides a soup extracted from choerospondias axillaris fruits as a raw material by water separation. The soup is both external and internal. The soup has antioxidation, anticancer and antisenescence functions. The soup has good curative effects for treating a cancer in middle and advanced stages after various operations, hypertension, diabetes, obesity, arthritis and climacteric metancholia, and has unique curative effects for treating burn and scald, electrochemical burn and chemical medicine burn. The soup can be used without skin-grafting, secondary fester and sequelae. The soup has advantages of short cure time and substantial curative effect, and is worthy of popularization and application.
The invention discloses a method for synthesizing selenized fenugreek polysaccharides. The method comprises the following steps: preparing a fenugreek polysaccharide formamide solution; preparing an ionic liquid; activating selenous acid by using the ionic liquid; and synthesizing the selenized fenugreek polysaccharides. The ionic liquid is utilized to activate the selenous acid to prepare the high-activity selenization reagent, and the bioactive selenized fenugreek polysaccharides are efficiently synthesized under mild conditions. The selenium content is up to 27554-29773 mu g/g. The reagent is friendly to the environment and simple to prepare, does not need any toxic seleniferous intermediate, and does not have the waste liquid discharge, thereby effectively shortening the reaction required lime, and widening the application range of the fenugreek polysaccharides as natural active substances. The activity test indicates that the synthesized selenized fenugreek polysaccharides have obvious in-vitro inhibiting actions on HepG2 liver cancer cells.
Severe hypertension occurred at a higher incidence in patients receiving bevacizumab products as compared to patients receiving chemotherapy alone. Across clinical studies, the incidence of Grades 3–4 hypertension ranged from 5% to 18%.

Monitor blood pressure every two to three weeks during treatment with VEGZELMA. Treat with appropriate anti-hypertensive therapy and monitor blood pressure regularly. Continue to monitor blood pressure at regular intervals in patients with VEGZELMA-induced or -exacerbated hypertension after discontinuing VEGZELMA. Withhold VEGZELMA in patients with severe hypertension that is not controlled with medical management; resume once controlled with medical management. Discontinue in patients who develop hypertensive crisis or hypertensive encephalopathy.
5.1 Somnolence   
In clinical trials the occurrence of somnolence, fatigue, and asthenia has been reported in some patients under therapy with levocetirizine dihydrochloride. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness, and motor coordination such as operating machinery or driving a motor vehicle after ingestion of levocetirizine dihydrochloride. Concurrent use of levocetirizine dihydrochloride with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur.   
5.2 Urinary Retention   
Urinary retention has been reported post-marketing with levocetirizine dihydrochloride. Levocetirizine dihydrochloride should be used with caution in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine dihydrochloride may increase the risk of urinary retention. Discontinue levocetirizine dihydrochloride if urinary retention occurs.
BACKGROUND: Peroral endoscopic myotomy (POEM) has emerged as a widely accepted treatment for achalasia, with limited studies for over 2 years. Additionally, traditional measurements of achalasia after POEM have deficiencies. The study aimed to analyze the long-term outcomes of POEM under different criteria.
METHODS: Patients with achalasia who received POEM between November 2012 and March 2021 were recruited. Patients and characteristics were shown, and risk factors related to two novel definitions of recurrence, symptomatic reflux, and reflux esophagitis were analyzed.
RESULTS: Three hundred and twenty-one patients were included. At a median follow-up of 52 months, twenty-three failures happened (7.17%) under the modified criterion, and forty-seven failures occurred (14.64%) under the normal standard. Hospitalization (P = 0.027) and esophageal myotomy length (P = 0.039) were significantly associated with long-term efficacy under the modified and normal criteria, respectively. Fifty-two patients (16.20%) reported reflux symptoms and endoscopy performed in 88 patients revealed reflux esophagitis in 22 cases (25.00%). There were no predictors in the analysis of symptomatic reflux and gender (P = 0.010), LESP (P = 0.013), IRP (P = 0.015), and the esophageal myotomy length (P = 0.032) were statistically related to reflux esophagitis.
CONCLUSION: POEM is an extremely safe and effective treatment for achalasia with long-term follow-up. Shorter hospitalization and shorter esophageal myotomy length may decrease the incidence of recurrence under the modified and normal criteria, respectively. Long-term outcomes of POEM are unpredictable. No risk factors were related to symptomatic reflux, and male patients with low preoperative LESP and IRP needed relatively shorter esophageal myotomy to prevent reflux esophagitis.
The Pittsburgh Sleep Quality Index (PSQI) is a self-reported questionnaire evaluating sleep quality based on seven domains of sleep disorders. However, the factor structure of PSQI needs to be well-established among medical students. This study was conducted to establish the factor structure of PSQI among medical students. Four-hundred and four medical students completed the PSQI. Considering each PSQI component as an "observed variable," exploratory factor analysis was conducted. Six models explaining the factor structure of PSQI were compared by confirmatory factor analysis to achieve the best model. All PSQI components were loaded on three factors. The first factor included sleep duration and habitual sleep efficiency, the second was subjective sleep quality and sleep latency, and the third was sleep disturbances, sleeping medications, and daytime dysfunction (root mean square error of approximation =  < 0.01, goodness of fit index = 0.99). The differences in Bayesian information criteria and root mean square error of approximation between our best-fit model and each of the other resulted in rejection of all other Models. Besides confirming the structural validity among medical students, our findings indicated the adequacy of the 3-factor structure of PSQI, including sleep efficiency, perceived sleep quality, and daily disturbances in this population.
The present invention, in some embodiments thereof, generally relates to methods and devices for determining the health status of a subject, e.g., whether the subject has a disease or other condition. In some embodiments, a plurality or mixture of species may be differentially solubilized in a single two-phase aqueous system, or other multi-phase aqueous system. The nature or degree of the solubilization of the species may be used to determine the health status of a subject. For example, some embodiments are directed to devices and methods for determining a disease or other condition as a function of the changes to the structure of two or more species. The species may be selected based on their differential solubility behavior in a two-phase or other multi-phase aqueous system. Preferential enrichment of the species concentrations in one of the phases, and/or the ratios of species in the phases may be determined, and in some cases compared to their respective values for healthy and/or diseased subjects to determine the health status of the subject.
<P>PROBLEM TO BE SOLVED: To provide a compound and the like each usable as a vehicle effective for the effective delivery of a large and complex factor(e.g. polynucleotide) to cells.  <P>SOLUTION: The compound is a lipid-conjugated polyamide compound of specific general formula. A composition containing the compound is also provided. These are particularly useful for delivering a biologically active factor to cells. A method for inducing taking-in a biologically active factor into cells is also provided, comprising obtaining an effective amount of the above biologically active factor and the composition followed by contacting a biological sample(where, the sample includes cells) with the effective dose of the composition.  <P>COPYRIGHT: (C)2007,JPO&INPIT
When the natural exposure to elevated aeroallergens produces symptoms as described under Clinical Pharmacology, specific diagnosis and therapeutic procedures are indicated. Clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. Diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. Specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. When immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. An orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11

THIS PRODUCT IS NOT INTENDED FOR TREATMENT OF PATIENTS WHO DO NOT MANIFEST IMMEDIATE HYPERSENSITIVITY REACTIONS TO THE ALLERGENIC EXTRACT FOLLOWING SKIN TESTING.
In Nepal, over 1 million individuals have tested positive for SARS-CoV-2. We sought to describe the frequency of nonrecovery from this infection at 6 months and associated symptoms. We conducted a retrospective cohort study of 6142 women who had positive and negative PCR tests for this infection 6 months previously at 3 institutions in Kathmandu. In telephone interviews women provided information on 22 symptoms and their intensities, health status and history, and functional status. Of 3732 women who had tested PCR positive, 630 (16.9%) reported that they were unrecovered. These 630 unrecovered women were distinguished statistically from the 3102 recovered women by more frequent histories of allergies, rheumatoid disease, BCG immunization, Covid vaccination, strep throat and recent URIs, and both weight gain and weight losses of more than 5 kg in the 6 months following testing, and stressful events in the preceding year. Fatigue, pain, difficulty remembering, shortness of breath, heat and cold intolerance and unrefreshing sleep were reported in 41.9% to 10.5% of these 630 unrecovered women. Six months after confirmed SARS-CoV-2 infection 16.9% of Nepali women have long-COVID manifested as an immune, metabolic, and hormonal systems disruptive and dysfunction syndrome.
Participants will train only with cognitive video games. The training regime consists of 40-50 min sessions, two sessions per week, for a total of eight weeks of individual training.
Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
A display card 100 for displaying solid cosmetic samples for sampling by the customer is described. A composition of solid cosmetic such as eyeshadow is mixed with volatile silicone to form a slurry. Samples 120-130 of the slurry are then applied to the display card by spraying or dropping onto the display card. The samples are then allowed to dry. Following this a protective coating such as waxed paper 170 is applied over the samples. The result is a display card with samples of a solid cosmetic. The potential customer can then remove the protective coating gaining access to the sample for applying a portion of a sample to the customer's skin. <IMAGE>
BACKGROUND: Bilateral masculinizing mastectomy is the most common gender-affirmation operation performed. Currently, there is lack of data regarding intraoperative and postoperative pain control for this population. It is the authors' aim to study the effects of the pectoral nerve (Pecs) I and II regional nerve blocks in patients undergoing masculinizing mastectomy.
METHODS: A randomized, double-blind, placebo-controlled trial was performed. Patients undergoing bilateral gender-affirmation mastectomy were randomized to receive either a Pecs block with ropivacaine or placebo injection. The patient, surgeon, and anesthesia team were blinded to the allocation. Intraoperative and postoperative opioid requirements were collected and recorded as morphine milligram equivalents (MME). Participants recorded postoperative pain scores at specific time points on the day of surgery through postoperative day 7.
RESULTS: Fifty patients were enrolled between July of 2020 and February of 2022. Twenty-seven were randomized to the intervention group and 23 to the control group, with 43 patients undergoing analysis. There was no significant difference in intraoperative MME between the Pecs block group and the control group (9.8 versus 11.1; P = 0.29). In addition, there was no difference in postoperative MME between the groups (37.5 versus 40.0; P = 0.72). Postoperative pain scores were also similar between the groups at each specified time point.
CONCLUSIONS: There was no significant reduction in opioid consumption or postoperative pain scores in patients undergoing bilateral gender-affirmation mastectomy who received a regional anesthetic when compared with placebo. In addition, a postoperative opioid-sparing approach may be appropriate for patients undergoing bilateral masculinizing mastectomy.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, I.
The invention discloses hemorrhoids unguent and a preparing method of the hemorrhoids unguent. The hemorrhoids unguent comprises a raw material composite and Vaseline. The raw material composite is composed of, by weight, 26-34 parts of sophora flowers, 29-31 parts of pollen pini, 19-21 parts of borneol, 9-11 parts of realgar and 9-11 parts of alum. The preparing method of the hemorrhoids unguent comprises the following steps that (1) smashing is conducted, the raw material composite is taken out according to the ratio, the sophora flowers and the pollen pini are mixed and burned until the sophora flowers and the pollen pini are burnt into charcoal fine powder; (2) unguent is prepared, the charcoal fine powder obtained in the step (1) is mixed with other raw medical materials, and the charcoal fine powder and other raw medical materials are added to the Vaseline and stirred evenly until the mixture is stirred to unguent. The hemorrhoids unguent is convenient to use, free of the side effect, low in recurrence rate, fast in effect production, capable of replacing an operation, an injection and taking of medicine, and capable of thoroughly curing hemorrhoids. The preparing method of the hemorrhoids unguent is simple and low in production cost.
The invention relates to a traditional Chinese medicine formula, and especially relates to a traditional Chinese medicine for treating shoulder periarthritis. As the people grow old, the happening rate of shoulder periarthritis is increasing. There are many methods for treating shoulder periarthritis, such as shoulder periarthritis traction method, massage therapy, physical therapy, nerve block method, drug treatment, surgery, and the like; the shoulder periarthritis traction method cannot cure the root of shoulder periarthritis, massage therapy is difficult to handle, the effect of physical therapy is indefinite and not good, the nerve block method probably cannot maintain a lasting effect, the drug treatment can only relieve the symptom, and the surgery treatment has the disadvantages of high cost, huge pain to patients, and high risk. The invention provides a traditional Chinese medicine for treating shoulder periarthritis, and the traditional Chinese medicine has the advantages of good curative effect and low price. The traditional Chinese medicine is composed of the following raw medicinal materials by weight: 40 to 60 grams of raw haw, 30 to 40 grams of processed nux vomica, 40 to 60 grams of mulberry, 30 to 50 grams of sand earthworm, 20 to 30 grams of mulberry twig, 20 to 30 grams of dark plum, 30 to 40 grams of white flower, 30 to 40 grams of peach seed, 10 to 30 grams of white peony root, 10 to 30 grams of buck grass, 10 to 20 grams of rhizoma drynariae, 15 to 25 grams of rhizoma corydalis processed with vinegar, 10 to 20 grams of frankincense, 10 to 20 grams of turmeric, 10 to 20 grams of cassia twig, 10 to 20 grams of cortex acanthopanacis, 10 to 20 grams of clematis root, 10 to 20 grams of rhizoma cyperi processed with vinegar, 8 to 12 grams of licorice, and 12 to 20 grams of kudzu vine root. The traditional Chinese medicine has the functions of freeing the channels and collaterals, eliminating stagnation, moving impediment, relieving pains, and smoothing the joints; and has the advantages of short treatment time, low cost, and good treatment effect.
Prior to standard of care surgery, patients treated at dose levels 1 and 2 receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1 of each cycle. Treatment repeats every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients treated at dose level 3 receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on days 1, 4, 8, and 15 for 1 cycle. Patients also undergo ECHO and collection of blood samples throughout the trial and may undergo biopsy on trial.
Sodium Chloride Injection, USP 0.9% is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. It contains no bacteriostatic antimicrobial agents or added buffer. The nominal pH is 5.5 (4.5 to 7.0).

Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment. Sodium Chloride Injection, USP, 0.9% contains 9 g/L Sodium Chloride, USP (NaCl) with a calculated osmolarity of approximately 308 mOsmol/L. It contains 154 mEq/L sodium and 154 mEq/L chloride.

The syringe component of Sodium Chloride Injection, USP, 0.9% is manufactured with polypropylene and luer lock.

The syringe is not made with natural rubber latex. The syringe is not made with DEHP. This product contains no preservative. The syringes require no vapor barrier to maintain the proper drug concentration. The empirical formula for sodium chloride is NaCl and the molecular weight is 58.44 g/mol.

Supplied as single use syringes.
INTRODUCTION: Total joint replacement has become significantly more common as a treatment for advanced trapeziometacarpal joint osteoarthritis in recent years. The latest generation of prostheses with dual-mobility designs leads to very good functional results and low rates of loosening and dislocation in the short and medium term. Biomechanical studies showed that central placement and parallel alignment of the cup with respect to the proximal articular surface of the trapezium are crucial for both cup stability and prevention of dislocation. Despite correct positioning of the guidewire, incorrect placement or tilting of the inserted cup may occur, requiring immediate intraoperative revision.
METHODS: The existing spherical and conical cup models in sizes 9 mm and 10 mm were transferred to a computer-aided design dataset. Depending on the intraoperative complication (tilting or incorrect placement), the revision options resulting from the various combinations of cup type and size were simulated and analyzed according to the resulting defect area and bony contact area.
RESULTS: In well centered cups, a size 9 conical cup could be replaced by a size 9 spherical cup and still be fixed by press-fit. Conversely, a size 9 spherical cup could not be replaced by a size 9 conical cup, but only by a size 10 cup, of whatever shape. When a size 9 conical cup was tilted up to 20°, the best revision option was to resect the sclerotic margin and insert a size 10 conical cup deeper into the cancellous bone, to achieve the largest contact area with the surrounding bone. When a size 9 cup of whatever shape was poorly centered (misplaced with respect to the dorsopalmar or radioulnar line of the trapezium), placement should be corrected using a size 10 cup, combined with autologous bone grafting of the defect. Again, the size 10 conical cup showed the largest bony contact area.
CONCLUSION: Our computer-based measurements suggested options for intraoperative cup revision depending on cup shape and size and on type of misalignment with resulting bone defects. These suggestions, however, need to be confirmed in anatomic specimens before introducing them into clinical practice.
The presence of lymph node metastases indicates a poor prognosis, with a marked decrease in 5-year survival rate. Lymph node involvement is an important factor in the choice of adjuvant treatment in gynaecological malignancies. Surgical lymphadenectomy is the gold standard for the diagnosis of lymph node metastases. This is a highly specialized procedure with increase in operative time and cost, and risk of surgery-related morbidity. Therefore, a non-invasive technique that accurately identifies lymph node metastasis would be beneficial. Diffusion Weighted whole body Imaging with Background Signal suppression (DWIBS) is a new imaging technique, which lightens lymph nodes and possibly differentiates normal and hyperplastic from metastatic lymph nodes. Cancer metastases in lymph nodes may be associated with alterations in water diffusivity and microcirculation within the node. It is also likely that cell density might play an important role. So far, no feasibility studies have will be evaluated for its accuracy, effectiveness, and feasibility in detecting lymph node metastases in gynaecological malignancies, as a possible alternative for the surgical staging method. The accuracy of a pelvic lymph node dissection (reference test) will also be evaluated by performing a post-operative DWIBS scan.
India has the second highest number of HIV infections of any country in the world, and the epidemic continues unabated. This trial is focused on high risk men attending public STI clinics. A proposed 2 and a half year study, this trial will utilize the continuation of a randomized controlled trial of a behavioral intervention compared to HIV C\&T and STI treatment alone targeting HIV uninfected male STI patients. The specific aims are to complete the current behavioral intervention trial and to expand the current investigations to include: the evaluation of men who have sex with men as well as women and evaluate the use of alcohol to the entire sample of recruited men. STI patients will be recruited from three sites and if randomized will agree to a 12 month participation commitment. Strategies employed in both arms of the trial are simple and the fundamental components of an HIV prevention strategy. By demonstrating their effectiveness in India the hope is to encourage the public health leadership to adopt them and continue to change drug treatment availability.